Christi Wisniewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christi Wisniewski has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Arthur M. Mercurio
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA
9 shared publications - Sharon B. Cantor
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
8 shared publications - Jenna M. Whalen
University of Massachusetts Chan Medical School Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
7 shared publications - Nathan MacGilvary
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, United States of America
7 shared publications - Tokio Sano
University of Massachusetts Chan Medical School Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
7 shared publications - Ayush Kumar
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
BRCA-deficient cells have an inherent gap phenotype
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
BRCA-deficient cells have an inherent gap phenotype
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
Single-stranded DNA (ssDNA) gaps represent an underappreciated vulnerability that directly shapes therapeutic response in BRCA-deficient models. Current clinical biomarkers remain anchored to the double-strand break–centric model of homologous recombination deficiency, and there are currently no tools available to detect replication-associated gaps in the clinical setting. In this study, we developed a scalable, clinically adaptable assay that enables real-time, drug-free detection of gaps. This assay demonstrated that gaps are intrinsically elevated in BRCA-deficient cells independent of exogenous DNA damage. These gaps arose during DNA replication and were generated through PRIMPOL-dependent repriming at abasic sites and nuclease-mediated processing. Across diverse cell line models, PARP inhibitor (PARPi) sensitivity was associated with gap burden irrespective of BRCA status, extending the relevance of this vulnerability beyond canonical BRCA-mutant contexts. Integration with artificial intelligence–driven image analysis enabled automated, unbiased quantification of gap levels in xenograft tumor specimens. In BRCA-deficient xenografts, elevated gap levels were associated with PARPi sensitivity, supporting their translational relevance in relation to therapeutic response. Together, these findings establish ssDNA gaps as a real-time functional readout associated with chemotherapy response and introduce an assay with potential for future clinical translation. Significance:Single-stranded DNA gaps are an intrinsic feature of therapy-sensitive cancer cells, representing a functional biomarker that captures replication-associated vulnerabilities.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
Single-stranded DNA (ssDNA) gaps represent an underappreciated vulnerability that directly shapes therapeutic response in BRCA-deficient models. Current clinical biomarkers remain anchored to the double-strand break–centric model of homologous recombination deficiency, and there are currently no tools available to detect replication-associated gaps in the clinical setting. In this study, we developed a scalable, clinically adaptable assay that enables real-time, drug-free detection of gaps. This assay demonstrated that gaps are intrinsically elevated in BRCA-deficient cells independent of exogenous DNA damage. These gaps arose during DNA replication and were generated through PRIMPOL-dependent repriming at abasic sites and nuclease-mediated processing. Across diverse cell line models, PARP inhibitor (PARPi) sensitivity was associated with gap burden irrespective of BRCA status, extending the relevance of this vulnerability beyond canonical BRCA-mutant contexts. Integration with artificial intelligence–driven image analysis enabled automated, unbiased quantification of gap levels in xenograft tumor specimens. In BRCA-deficient xenografts, elevated gap levels were associated with PARPi sensitivity, supporting their translational relevance in relation to therapeutic response. Together, these findings establish ssDNA gaps as a real-time functional readout associated with chemotherapy response and introduce an assay with potential for future clinical translation. Significance:Single-stranded DNA gaps are an intrinsic feature of therapy-sensitive cancer cells, representing a functional biomarker that captures replication-associated vulnerabilities.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
The gap detection assay detects gaps induced by genotoxic agents and trapping by PARPi.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
The gap detection assay detects gaps induced by genotoxic agents and trapping by PARPi.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
The gap detection assay detects gaps linked to replication, abasic sites, PRIMPOL, and resection in BRCA1-deficient cells.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
The gap detection assay detects gaps linked to replication, abasic sites, PRIMPOL, and resection in BRCA1-deficient cells.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
AI-based gap detection assay quantification is associated with PARPi sensitivity in BRCA1-deficient tumors.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
AI-based gap detection assay quantification is associated with PARPi sensitivity in BRCA1-deficient tumors.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
The gap detection assay detects gaps linked to replication, abasic sites, PRIMPOL, and resection in BRCA1-deficient cells.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
The gap detection assay detects gaps linked to replication, abasic sites, PRIMPOL, and resection in BRCA1-deficient cells.
- Open Access
- 8 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (22) , 5822-5836
Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
Single-stranded DNA (ssDNA) gaps represent an underappreciated vulnerability that directly shapes therapeutic response in BRCA-deficient models. Current clinical biomarkers remain anchored to the double-strand break–centric model of homologous recombination deficiency, and there are currently no tools available to detect replication-associated gaps in the clinical setting. In this study, we developed a scalable, clinically adaptable assay that enables real-time, drug-free detection of gaps. This assay demonstrated that gaps are intrinsically elevated in BRCA-deficient cells independent of exogenous DNA damage. These gaps arose during DNA replication and were generated through PRIMPOL-dependent repriming at abasic sites and nuclease-mediated processing. Across diverse cell line models, PARP inhibitor (PARPi) sensitivity was associated with gap burden irrespective of BRCA status, extending the relevance of this vulnerability beyond canonical BRCA-mutant contexts. Integration with artificial intelligence–driven image analysis enabled automated, unbiased quantification of gap levels in xenograft tumor specimens. In BRCA-deficient xenografts, elevated gap levels were associated with PARPi sensitivity, supporting their translational relevance in relation to therapeutic response. Together, these findings establish ssDNA gaps as a real-time functional readout associated with chemotherapy response and introduce an assay with potential for future clinical translation. Significance: Single-stranded DNA gaps are an intrinsic feature of therapy-sensitive cancer cells, representing a functional biomarker that captures replication-associated vulnerabilities.
- 8 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (22) , 5822-5836
Open AccessDetection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response
Single-stranded DNA (ssDNA) gaps represent an underappreciated vulnerability that directly shapes therapeutic response in BRCA-deficient models. Current clinical biomarkers remain anchored to the double-strand break–centric model of homologous recombination deficiency, and there are currently no tools available to detect replication-associated gaps in the clinical setting. In this study, we developed a scalable, clinically adaptable assay that enables real-time, drug-free detection of gaps. This assay demonstrated that gaps are intrinsically elevated in BRCA-deficient cells independent of exogenous DNA damage. These gaps arose during DNA replication and were generated through PRIMPOL-dependent repriming at abasic sites and nuclease-mediated processing. Across diverse cell line models, PARP inhibitor (PARPi) sensitivity was associated with gap burden irrespective of BRCA status, extending the relevance of this vulnerability beyond canonical BRCA-mutant contexts. Integration with artificial intelligence–driven image analysis enabled automated, unbiased quantification of gap levels in xenograft tumor specimens. In BRCA-deficient xenografts, elevated gap levels were associated with PARPi sensitivity, supporting their translational relevance in relation to therapeutic response. Together, these findings establish ssDNA gaps as a real-time functional readout associated with chemotherapy response and introduce an assay with potential for future clinical translation. Significance: Single-stranded DNA gaps are an intrinsic feature of therapy-sensitive cancer cells, representing a functional biomarker that captures replication-associated vulnerabilities.
- Open Access
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (42) , eadx3050
Resistance to radiation enhances metastasis by altering RNA metabolism
The cellular programs that mediate therapy resistance are often important drivers of metastasis, a phenomenon that needs to be understood better to improve screening and treatment options for patients with cancer. Although this issue has been studied extensively for chemotherapy, less is known about a causal link between resistance to radiation therapy and metastasis. We investigated this problem in triple-negative breast cancer and established that radiation-resistant tumor cells have enhanced metastatic capacity. Resistance to radiation increases the expression of integrin β3 ( ITGB3 ), which promotes enhanced migration and invasion. Bioinformatic analysis and subsequent experimentation revealed an enrichment of RNA metabolism pathways that stabilize ITGB3 transcripts. Specifically, the RNA binding protein heterogeneous nuclear ribonucleoprotein L ( HNRNPL ), whose expression is regulated by Nrf2, mediates the formation of circular RNAs that sponge the family of let-7 microRNAs that target ITGB3 . Collectively, our findings identify a mechanism of radiation-induced metastasis that is driven by alterations in RNA metabolism.
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (42) , eadx3050
Open AccessResistance to radiation enhances metastasis by altering RNA metabolism
The cellular programs that mediate therapy resistance are often important drivers of metastasis, a phenomenon that needs to be understood better to improve screening and treatment options for patients with cancer. Although this issue has been studied extensively for chemotherapy, less is known about a causal link between resistance to radiation therapy and metastasis. We investigated this problem in triple-negative breast cancer and established that radiation-resistant tumor cells have enhanced metastatic capacity. Resistance to radiation increases the expression of integrin β3 ( ITGB3 ), which promotes enhanced migration and invasion. Bioinformatic analysis and subsequent experimentation revealed an enrichment of RNA metabolism pathways that stabilize ITGB3 transcripts. Specifically, the RNA binding protein heterogeneous nuclear ribonucleoprotein L ( HNRNPL ), whose expression is regulated by Nrf2, mediates the formation of circular RNAs that sponge the family of let-7 microRNAs that target ITGB3 . Collectively, our findings identify a mechanism of radiation-induced metastasis that is driven by alterations in RNA metabolism.
- 21 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (2) , 278-291
Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability
Tumors lacking the BRCA1 and BRCA2 (BRCA) hereditary breast cancer genes display heightened sensitivity to anti-cancer treatments, such as inhibitors of poly (ADP-ribose) polymerase 1 (PARP1). However, when resistance develops, treatments are lacking. Using CRISPR technology, we discovered that enhancing homologous recombination through increased DNA end resection in BRCA1-deficient cells by loss of the 53BP1–Shieldin complex—which is associated with resistance to PARP inhibitors—also heightens sensitivity to DNA nicks. The sensitivity is caused by hyper-resection of nicks into extensive single-stranded regions that trigger cell death. Based on these findings and that nicks limit tumor formation in mice, we propose nickases as a tool for personalized medicine. Moreover, our findings indicate that restricting nick expansion is a critical function of the 53BP1–Shieldin complex.
- 21 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (2) , 278-291
Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability
Tumors lacking the BRCA1 and BRCA2 (BRCA) hereditary breast cancer genes display heightened sensitivity to anti-cancer treatments, such as inhibitors of poly (ADP-ribose) polymerase 1 (PARP1). However, when resistance develops, treatments are lacking. Using CRISPR technology, we discovered that enhancing homologous recombination through increased DNA end resection in BRCA1-deficient cells by loss of the 53BP1–Shieldin complex—which is associated with resistance to PARP inhibitors—also heightens sensitivity to DNA nicks. The sensitivity is caused by hyper-resection of nicks into extensive single-stranded regions that trigger cell death. Based on these findings and that nicks limit tumor formation in mice, we propose nickases as a tool for personalized medicine. Moreover, our findings indicate that restricting nick expansion is a critical function of the 53BP1–Shieldin complex.
- 3 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (694) , eade5855
Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer
Prostate cancers are largely unresponsive to immune checkpoint inhibitors (ICIs), and there is strong evidence that programmed death-ligand 1 (PD-L1) expression itself must be inhibited to activate antitumor immunity. Here, we report that neuropilin-2 (NRP2), which functions as a vascular endothelial growth factor (VEGF) receptor on tumor cells, is an attractive target to activate antitumor immunity in prostate cancer because VEGF-NRP2 signaling sustains PD-L1 expression. NRP2 depletion increased T cell activation in vitro. In a syngeneic model of prostate cancer that is resistant to ICI, inhibition of the binding of VEGF to NRP2 using a mouse-specific anti-NRP2 monoclonal antibody (mAb) resulted in necrosis and tumor regression compared with both an anti–PD-L1 mAb and control immunoglobulin G. This therapy also decreased tumor PD-L1 expression and increased immune cell infiltration. We observed that the NRP2 , VEGFA , and VEGFC genes are amplified in metastatic castration-resistant and neuroendocrine prostate cancer. We also found that individuals with NRP2 High PD-L1 High metastatic tumors had lower androgen receptor expression and higher neuroendocrine prostate cancer scores than other individuals with prostate cancer. In organoids derived from patients with neuroendocrine prostate cancer, therapeutic inhibition of VEGF binding to NRP2 using a high-affinity humanized mAb suitable for clinical use also diminished PD-L1 expression and caused a substantial increase in immune-mediated tumor cell killing, consistent with the animal studies. These findings provide justification for the initiation of clinical trials using this function-blocking NRP2 mAb in prostate cancer, especially for patients with aggressive disease.
- 3 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (694) , eade5855
Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer
Prostate cancers are largely unresponsive to immune checkpoint inhibitors (ICIs), and there is strong evidence that programmed death-ligand 1 (PD-L1) expression itself must be inhibited to activate antitumor immunity. Here, we report that neuropilin-2 (NRP2), which functions as a vascular endothelial growth factor (VEGF) receptor on tumor cells, is an attractive target to activate antitumor immunity in prostate cancer because VEGF-NRP2 signaling sustains PD-L1 expression. NRP2 depletion increased T cell activation in vitro. In a syngeneic model of prostate cancer that is resistant to ICI, inhibition of the binding of VEGF to NRP2 using a mouse-specific anti-NRP2 monoclonal antibody (mAb) resulted in necrosis and tumor regression compared with both an anti–PD-L1 mAb and control immunoglobulin G. This therapy also decreased tumor PD-L1 expression and increased immune cell infiltration. We observed that the NRP2 , VEGFA , and VEGFC genes are amplified in metastatic castration-resistant and neuroendocrine prostate cancer. We also found that individuals with NRP2 High PD-L1 High metastatic tumors had lower androgen receptor expression and higher neuroendocrine prostate cancer scores than other individuals with prostate cancer. In organoids derived from patients with neuroendocrine prostate cancer, therapeutic inhibition of VEGF binding to NRP2 using a high-affinity humanized mAb suitable for clinical use also diminished PD-L1 expression and caused a substantial increase in immune-mediated tumor cell killing, consistent with the animal studies. These findings provide justification for the initiation of clinical trials using this function-blocking NRP2 mAb in prostate cancer, especially for patients with aggressive disease.